In multiple sclerosis (MS) T cells aberrantly recognize self-peptides of the myelin sheath and attack the central nervous system (CNS). Antigen-specific peptide immunotherapy, which aims to restore tolerance while avoiding the use of non-specific immunosuppressive drugs, is a promising approach to combat autoimmune disease, but the cellular mechanisms behind successful therapy remain poorly understood. Myeloid-derived suppressor cells (MDSCs) have been studied intensively in the field of cancer and to a lesser extent in autoimmunity. Because of their suppressive effect on the immune system in cancer, we hypothesized that the development of MDSCs and their interaction with CD4 + T cells could be beneficial for antigen-specific immunotherapy. Hence, changes in the quantity, phenotype and function of MDSCs during tolerance induction in our model of MS were evaluated. We reveal, for the first time, an involvement of a subset of MDSCs, known as polymorphonuclear (PMN)-MDSCs, in the process of tolerance induction. PMN-MDSCs were shown to adopt a more suppressive phenotype during peptide immunotherapy and inhibit CD4 + T-cell proliferation in a cell-contact-dependent manner, mediated by arginase-1. Moreover, increased numbers of tolerogenic PMN-MDSCs, such as observed over the course of peptide immunotherapy, were demonstrated to provide protection from disease in a model of experimental autoimmune encephalomyelitis.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) where immune cells attack myelinated axons of the brain and spinal cord. 1 The ideal treatment of MS would be to specifically target the disease-causing immune cells without compromising the broader function of the immune system. A promising approach to the treatment of MS relies on the use of soluble, synthetic peptides, based on the sequence of known disease-associated antigens, to promote tolerance induction. In the Tg4 model of experimental autoimmune encephalomyelitis (EAE), T cells express a transgenic T-cell receptor specific for the immunodominant epitope of myelin basic protein, MBP (Ac1-9). 2 The development of induced EAE in this model can be prevented by repetitive administration of the cognate peptide. 3 This is characterized by the induction of anergy in CD4 + T cells and a switch in serum cytokines from a dominant interferon-c response towards interleukin-10 (IL-10). A dose escalation protocol for subcutaneous delivery of the high self-antigen doses, required for effective tolerance induction, was shown to be highly effective and safe. 4, 5 Abbreviations: APC, antigen-presenting cell; AUC, area under the curve; BLN, brachial lymph node; CNS, central nervous system; EAE, experimental autoimmune encephalomyelitis; EDI, escalating dose immunotherapy; IL-10, interleukin-10; ILN, inguinal lymph node; iNOS, inducible nitric oxide synthase; MBP, myelin basic protein; MDSC, myeloid-derived suppressor cell; M-MDSC, monocytic MDSC; MS, multiple sclerosis; PMN-MDSC, polymorphonuclear MDSC; Tag, antigen-experienced T; TCR, T-cell receptor; Th1, T helper type 1; Tnaiv, naive T; Treg, regulatory T cells 
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Escalating dose immunotherapy (EDI) leads to an upregulation of co-inhibitory molecules including LAG-3, TIGIT, TIM-3 and PD1 on CD4 + T cells. 5 Another study previously found that expression of TIM-3 on T cells resulted in an increase in a population of CD11b + Ly6G + cells. 6 These innate cells, known as myeloid-derived suppressor cells (MDSC), were first described more than 30 years ago in cancer patients. 7 Since then, their detrimental role in cancer has been well characterized. These immature myeloid cells accumulate in tumours and contribute highly to immune escape by suppressing antigenspecific T-cell responses. 8, 9 Only more recently has a potential beneficial role for MDSC in autoimmune diseases, including type 1 diabetes 10 and EAE 11 become appreciated, demonstrating that MDSC can limit T-cellmediated pathology and tissue injury. In mice, MDSC are broadly defined as CD11b + Gr1 + cells. Anti-Gr1 antibodies recognize two targets, LY6G and LY6C. A further distinction in MDSC subsets can be made based on their differential LY6G and LY6C expression. 12 13 MDSC use multiple mechanisms to suppress Tcell proliferation. The majority of studies have found an involvement of the enzymes arginase-1 and inducible nitric oxide synthase (iNOS) in MDSC-mediated suppression of T cells. 14, 15 More recently, other mechanisms of suppression deployed by MDSC have been revealed, including the production of the enzyme indoleamine 2,3-dioxygenase and IL-10. 16, 17 In addition to these soluble factors, cell surface molecules, including PD-L1, Galectin-9, CD40 and CD80, have been suggested to play a role in the suppression of T cells. 6, [18] [19] [20] Here, we reveal for the first time a previously unknown role for PMN-MDSC in antigen-specific tolerance induction.
Materials and methods

Mice
All animal experiments were carried out under a UK Home Office Project Licence and approved by the University of Bristol ethical review committee. Mice were bred and kept under specific pathogen-free conditions.
The Tg4 T-cell receptor (TCR)-transgenic mouse was described previously. 21 CD4 + T cells in this model express a Va4 Vb8.2 transgenic TCR specific for the acetylated nineresidue peptide of MBP (Ac1-9) in the context of I-Au.
Peptides MBP Ac1-9 (4K) (Ac-ASQKRPSQR) and the high-affinity analogue MBP Ac1-9 (4Y) (Ac-ASQYRPSQR) were customsynthesized by GL Biochem (Shanghai, China).
Escalating-dose peptide immunotherapy
For tolerance induction, mice were treated subcutaneously every 3-4 days with a total of six doses of MBP Ac1-9 (4Y) in PBS in increasing doses: 0Á08, 0Á8, 8 lg, 3 9 80 lg.
Flow cytometry analysis
The following anti-mouse antibodies (BioLegend, San Diego, CA; unless stated otherwise) were used: CD4 A700, IL-17A-Peridinin chlorophyll protein-Cy5.5 (eBioscience, San Diego, CA), interferon-c allophycocyanin (eBioscience), Foxp3-phycoerythrin (eBioscience), Ly6G A700, Ly6C allophycocyanin-Cy7, CD11b-Peridinin chlorophyll protein-Cy5.5, Galectin-9-phycoerythrin, CD80 BV421, CD86 BV605, CD40-phycoerythrin-Cy7, PD-L1-allophycocyanin, MHCII allophycocyanin-Cy7. Fixable viability dyeeFluor780 (eBioscience) was used to exclude dead cells. Samples for intracellular staining were activated with 5 ng/ ml PMA (Sigma, St Louis, MO) plus 500 ng/ml Ionomycin (Sigma) and Golgi Stop (BD Bioscience, Franklin Lakes, NJ) for 3 hr. Cell proliferation dye-ef450 (CPD-ef450; eBioscience) was used to visualize cell divisions or calculate division and proliferation indexes. FACS acquisition was performed on an LSR-II flow cytometer (Becton-Dickinson, Franklin Lakes, NJ) and results were analysed using FLOWJO software (TreeStar Inc., Ashland, OR).
Magnetic cell isolation
Naive CD4
+ T cells were isolated using the MagniSort TM Mouse CD4 Naive T cell Enrichment Kit (#8804-6824-74) from eBioscience according to the instructions. Mouse CD11c + dendritic cells from the spleen were isolated using the CD11c Microbeads Kit from MACS Miltenyi Biotec (Bergisch Gladbach, Germany) (#130-052-001).
[H]Thymidine proliferation assay
For some 3 [H]thymidine proliferation assays, 1 9 10 6 splenocytes or 2 9 10 5 lymph node cells were cultured, in triplicate, with titrated doses of MBP Ac1-9 (4K) in a 96-well round-bottom plate. For other experiments, CD4 + T cells were magnetically isolated from the spleen and a 3 [H]thymidine assay was set up with titrated doses of MBP Ac1-9 (4K) and irradiated antigen-presenting cells (APC). Cells were cultured for 3 days at 37°in a CO 2 incubator and 0Á5 lCi of 3 [H]thymidine was added to wells for 16 hr before measurement using a 1450 Micro-b counter (Wallac, Turku, Finland).
In vitro suppression assay PMN-MDSC and antigen-experienced CD4 + T cells (Tag) from MBP Ac1-9 (4Y)-treated mice were FACS sorted.
PMN-MDSC and CD4
+ T cells were either co-cultured at a ratio of 1 : 3 together with CD11c + cells as APC in an APC : T-cell ratio of 1 : 10 and MBP Ac1-9 (4K)-peptide (10 lg/ml) or at a 1 : 1 ratio in the presence of 1 lg/ml plate-bound anti-CD3 and 2 lg/ml anti-CD28 (both from BioXCell, West Lebanon, NH). Both CD4 + Tnaiv and Tag populations were labelled with cell proliferation dye eFluor â 450 before co-culture. CD4 + T cells (1 9 10 6 ) were used for the co-culture for 4 days in a 48-well plate or 1 9 10 5 T cells in a 96-well plate. Some experiments were performed in the presence of neutralizing antibodies against: PD-L1, Galectin-9, CD40, CD80, CD86 (all from BioLegend) and IL-10 receptor (IL-10R) (BioXCell). For experiments regarding the effect of iNOS and arginase-1, 0Á5 mM NG-monomethyl-L-arginine (L-NMMA; Merck, Kenilworth, NJ) or 0Á5 mM S-(2-boronoethyl)-L-cysteine (BEC; Santa Cruz Biotechnology, Dallas, TX) respectively were added at the beginning of the culture. To investigate if the suppressive effect of PMN-MDSC is contact dependent, PMN-MDSC and CD4 + T cells were separated during the co-culture using a transwell assay (Corning, Corning, NY).
Induction and evaluation of EAE
EAE was induced by adoptive transfer of MBP Ac1-9 -specific T helper type 1 (Th1) cells. Briefly, Tg4 splenocytes were cultured for 5 days with 10 lg/ml MBP Ac1-9 (4K) and 5 ng/ml rmIL-12 (PeproTech, Rocky Hill, NJ), in the presence or absence of PMN-MDSC from tolerized Tg4 mice at a ratio of 1 : 3. After 72 hr, 20 U/ml rhIL-2 (R&D Systems. Minneapolis, MN) was added. In vitropolarized Th1 cells (5 9 10 6 ) were transferred into Tg4 animals. EAE was assessed twice daily with the following scoring system: 0, no signs; 1, flaccid tail; 2; impaired righting reflex and/or gait; 3, hind limb paralysis; 4, forelimb and hind limb paralysis; 5, moribund. (Fig. 1a) . In the spleen, inguinal lymph nodes (ILN), brachial lymph nodes (BLN), liver, lung, brain and spinal cord, the increase in the percentage of PMN-MDSC was more pronounced than that of M-MDSC. The lung was the only organ where we observed an increase in the frequency of both MDSC subsets. Considering these results, we decided to concentrate on PMN-MDSC for further experiments in which we assessed kinetics of MDSC changes during EDI. Expressed as a percentage of all leucocytes, the frequency of PMN-MDSC peaked after the third treatment in most organs other than the liver, where a significant increase was not established until the fifth treatment (Fig. 1b) . These experiments did not detect a statistically significant difference in the frequency of PMN-MDSC in the spinal cord. In addition to the frequency of PMN-MDSC, we also assessed absolute cell numbers for each organ (Fig. 1c) . These revealed a very similar pattern to the changes in the percentages.
Results
Increase in M-MDSC and PMN-MDSC during EDI
Dose escalation immunotherapy alters PMN-MDSC phenotype
The pronounced accumulation of PMN-MDSC after the third dose of peptide treatment led us to further investigate PMN-MDSC phenotype and function at this point. At this time, CD4 + T cells also start to undergo phenotypic changes that characterize the EDI protocol, namely the reduction in effector cytokines and the switch to IL-10 production in CD4 + T cells. 5 To further characterize the phenotype of PMN-MDSC and find ways in which they might influence the function of CD4 + T cells during the course of EDI, we investigated several markers that can affect CD4 + T-cell activation, including Galectin-9, PD-L1, CD40, CD80 and CD86. Representative staining of splenic PMN-MDSC is shown in Fig. 2(a) . The extent to which expression of these markers on PMN-MDSC was altered by EDI varied greatly depending on the location of the cells. For example, Galectin-9, PD-L1 and CD86 expression was increased on splenic PMN-MDSC compared with mice receiving PBS only as a control (Fig. 2b) . In other organs, such as the lung, Galectin-9 was increased but PD-L1 decreased in comparison to control-treated animals. There was no difference in CD40 expression in any of the organs evaluated. CD80 expression on PMN-MDSC trended towards a reduction in MBP Ac1-9 (4Y)-treated animals but this was significant only in the ILN.
Splenic PMN-MDSC suppress antigen-mediated proliferation of naive CD4 + T cells in vitro
To establish whether the PMN-MDSC that developed during EDI do indeed have immune regulatory properties, we first assessed their effect on CD4 + T-cell proliferation in vitro. Naive Tg4 CD4 + T cells (Tnaiv) and antigen-experienced CD4 + T cells (Tag) labelled with cell proliferation dye were co-cultured with CD11c + APC and 10 lg/ml of cognate peptide, in the presence or absence of PMN-MDSC from tolerized mice. After the 4-day coculture we measured CD4 + T-cell proliferation by flow cytometry and calculated the proliferation and division indexes. These experiments revealed that addition of PMN-MDSC to the T-cell cultures reduced the division index of proliferating naive CD4 + T cells, but to our surprise, PMN-MDSC were unable to reduce the proliferation of CD4 + Tag cells (Fig. 3a) . Importantly, addition of PMN-MDSC led to the expansion of CD4 + Foxp3 + regulatory T cells within the CD4 + T-cell population, although this only reached statistical significance for the combined data from five separate co-cultures with CD4 + Tag cells (Fig. 3b ). This could potentially be explained by the additional requirement of IL-2 for optimal CD4 + regulatory T cell expansion. This cytokine is secreted abundantly by CD4 + Tag cells but not naive CD4 + T cells.
Splenic PMN-MDSC suppress the proliferation of antigen-experienced CD4 + T cells activated by a polyclonal stimulus in vitro in a cell-contactdependent manner
Next we sought to determine if, in addition to suppression of an antigen-driven response, PMN-MDSC in the Tg4 model could act as suppressors of CD4 + T-cell proliferation activated in vitro without antigen or APC. Either Tnaiv or Tag cells, labelled with proliferation dye, were cultured together with PMN-MDSC from tolerized mice at a ratio of 1 : 1 for 4 days on a plate coated with anti-CD3 and anti-CD28. The suppressive activity of PMN-MDSC is their main characteristic but to make sure that this suppressive ability is the result of tolerance induction through EDI, we also isolated PMN-MDSC from PBStreated mice as a control and included those in our proliferation assays. PMN-MDSC from tolerized mice were found to be potent suppressors because they reduced the division index of both naive CD4 + T cells and antigenexperienced T cells significantly (Fig. 4a,b) . On the other hand, PMN-MDSC from control mice were not able to reduce the proliferation. In order to determine if the suppressive activity seen before is cell-contact-dependent, transwell experiments were performed. In these experiments, CD4
+ Tag cells were cultured on an anti-CD3 + anti-CD28-coated plate, separated by a membrane from splenic, FACS-sorted PMN-MDSC from tolerized Tg4 mice. Physical separation of PMN-MDSC and responder cells abrogated the suppressive effect on CD4 + T-cell proliferation, which suggested that the PMN-MDSC-mediated suppression of CD4 + T-cell proliferation is cell-contact-dependent (Fig. 3c ).
PMN-MDSC use a range of suppressive mechanisms
Several molecules have previously been suggested to mediate cell-contact-dependent suppression by PMN-MDSC. To investigate the molecules that may be involved in the suppressive effect of PMN-MDSC, blocking antibodies targeting molecules expressed on the surface of PMN-MDSC, namely Galectin-9, PD-L1, CD40, CD80 and CD86, or anti-IL-10R were added to the co-culture. The suppressive activity of PMN-MDSC was impaired under several of these conditions (Fig. 5a ). The addition of either anti-Galectin-9 or PD-L1 alone did not abrogate the suppressive activity of PMN-MDSC whereas the co-blockade of both ligands restored CD4 + T-cell proliferation at least in part, indicating a synergistic effect of Galectin-9 and PD-L1 in CD4 + T-cell suppression. The addition of blocking antibodies targeting the surface molecules CD40, CD80 or CD86 restored CD4 + T-cell proliferation in a similar fashion. Interleukin-10R signalling, however, did not appear to be essential for the suppressive activity of PMN-MDSC because in our in vitro suppression assay blockade of IL-10R (Fig. 5a ) did not alleviate CD4 + Tcell suppression. In addition to these cell surface antigens, soluble factors may still be involved in mediating suppression of CD4 + T cells in close proximity. Therefore, the possible role of iNOS and arginase-1 in mediating the suppression of CD4 + T-cell proliferation was investigated further by the addition of an inhibitor of iNOS, (L-NMMA), or an inhibitor of arginase-1, (S-(2-boronoethyl)-L-cysteine (BEC) to the suppression assay (Fig. 5b ). The addition of the arginase-1 inhibitor but not iNOS inhibitor abrogated the suppressive effect of PMN-MDSC. After checking for normality using the Shapiro-Wilk test the KruskalWallis test followed by Dunn's multiple comparison test for data that were not normally distributed was used (*P ≤ 0Á05, **P ≤ 0Á01, ***P ≤ 0Á001). In the spleen, inguinal lymph nodes (ILN), brachial lymph nodes (BLN) and lung each dot represents one individual mouse. In the liver in some cases cells from two animals were combined due to low cell numbers while in the central nervous systmem compartment each dot represents two individuals. n = 6, from two independent experiments. [Colour figure can be viewed at wileyonlinelibrary.com] M-MDSC in EAE positively correlated with disease severity and an improvement in pathology was accompanied by the reduction of these cells. 22, 23 However, in contrast to these studies their beneficial role in autoimmune diseases including EAE has become increasingly appreciated in recent years. 11 MDSC have been shown to be able to limit T-cell-mediated pathology and tissue injury as a result of their suppressive activity. 24 To assess the dynamics of PMN-MDSC during EAE in the Tg4 model, mice were treated with MBP Ac1-9 (4Y) to confer protection or with PBS only as a control, before the induction of EAE. Animals were culled at the peak of disease when PBStreated animals had an average disease score of 3 with complete hind limb paralysis (typically around day 14 after immunization). MBP Ac1-9 (4Y)-treated animals, which displayed no EAE symptoms, were taken at the same time of analysis. This confirmed that the frequency of PMN-MDSC was increased in animals in which EAE was induced compared with animals that were not primed for disease ( Fig. 6a compared with Fig. 1b) . In fact, the frequency of PMN-MDSC in mice with EAE was significantly higher in many of the organs examined than in mice that had been tolerized using EDI (Fig. 6a) . This then prompted the question whether qualitative changes may be more important for the immunosuppression of MDSC than quantitative changes. We therefore examined if the PMN-MDSC that arise during the development of EAE are phenotypically different from the ones that are generated during tolerization. Indeed, we observed a significant twofold lower expression of CD40 on PMN-MDSC in the spinal cord of mice with EAE compared with tolerized animals (Fig. 6b) . Furthermore, we detected a significantly lower expression of CD80 in the CNS compartment both in the brain and spinal cord, in tolerized animals compared with animals with EAE (Fig. 6b) . Finally, we found an increased expression of Galectin-9 and PD-L1 in both the spleen and lymph nodes in tolerized mice compared with control mice. However, the expression levels of these two markers in tolerized animals differ greatly between the spleen and inguinal lymph nodes in particular (Fig. 6b) . These findings hint at the possibility that phenotypic differences between the PMN-MDSC that develop after EAE development or after tolerization play a role in their functional dichotomy.
Splenectomy impairs the increase in the number of PMN-MDSC post EDI and prevents tolerance induction
We demonstrated an increase in the number of splenic PMN-MDSC, with a marker profile distinct from PMN-MDSC residing in the lymph nodes. Therefore, we wanted to further investigate the role of the spleen in tolerance induction. To achieve this, we performed splenectomies or sham operations before tolerance induction in Tg4 mice and analysis of the number of PMN-MDSC in the lymph nodes, lung or liver. As shown in Fig. 7(a,b) , splenectomy resulted in a statistically significant abrogation of the increase in the percentage of PMN-MDSC after EDI only in the ILN, although a similar trend was observed in the BLN and, in particular, the liver. Furthermore, we found that an intact spleen was essential for successful tolerance induction with MBP Ac1-9 (4Y). Removal of the spleen did not affect disease development in control-treated animals ( Fig. 7c) , whereas animals receiving MBP Ac1-9 (4Y)-treatment after a sham operation were largely protected against the induction of EAE. Their splenectomized counterparts all developed severe EAE. To allow for statistical analysis of the EAE scores of all animals over the course of the experiment, the area under the curve (AUC) was calculated and this demonstrated the same trend (Fig. 7c) .
Signalling through the IL-10R controls PMN-MDSC accumulation and phenotype
Our previous data showed that IL-10R signalling is not essential for the suppressive activity of PMN-MDSC because blockade of IL-10R signalling by an antibody did not alleviate CD4 + T-cell suppression in vitro (Fig. 5a ). However, we were still interested to know if IL-10 signalling affects the quantity and phenotype of PMN- After checking for normality using the ShapiroWilk test either analysis of variance followed by Sidak's multiple comparison test was performed for normally distributed data or the Kruskal-Wallis test followed by Dunn's multiple comparison test for data that were not normally distributed (*P ≤ 0Á05, **P ≤ 0Á01, ***P ≤ 0Á001, ****P ≤ 0Á0001). Data on the left of the vertical line had a normal distribution. In the spleen, inguinal lymph nodes (ILN), brachial lymph nodes (BLN) and lung each bar graph represents six individuals. In the liver in some cases cells from two animals were combined due to low cell numbers (n = 4) whereas in the central nervous system compartment each measurement contained cells from two animals. Kruskal-Wallis test followed by Dunn's multiple comparison test was applied to CD40, CD80 and CD86 data. n = 6, from two independent experiments. MDSC. First, we treated Tg4 IL-10 À/À mice with either PBS or MBP Ac1-9 (4Y) according to the EDI protocol until the third dose before isolating the spleen and lymph nodes to determine the quantity of PMN-MDSC. The significant increase of PMN-MDSC that results from peptide treatment in IL-10-sufficient animals was impaired in spleen and lymph nodes of Tg4 IL-10 À/À mice (Fig. 8a,   b ). This was true for both the increase in the percentage and absolute number of PMN-MDSC in the lymph nodes (Fig. 8a,b) . The fact that we detected fewer PMN-MDSC in IL-10 À/À animals could be either a direct effect because (Fig. 8c) . Moreover, the substantial increase of CD86 expression on PMN-MDSC from wild-type Tg4 mice in the spleen after EDI was impaired in Tg4 IL-10 À/ À mice (Fig. 8d) .
PMN-MDSC reduce CD4 + T-cell proliferation after antigen challenge in vivo
To test if, in addition to their inhibitory effect in vitro, PMN-MDSC are able to reduce the proliferation of CD4 + T cells in vivo, Tg4 mice received a cell transfer of 1Á5 9 10 6 FACS-sorted PMN-MDSC from tolerized mice intraperitoneally 3 days before priming with MBP Ac1-9 (4K) peptide in complete Freund's adjuvant at the base of the tail. Ten days later, spleen and ILN were harvested and a 3 [H]thymidine assay was set up. The proliferative response after re-stimulation in vitro with cognate peptide was significantly reduced in cells from the spleen but not the ILN from mice that had received a transfer of PMN-MDSC compared with mice that did not receive PMN-MDSC (Fig. 9a) . Next, to exclude the possibility that transferred PMN-MDSC still present in the whole splenocyte suspensions mediate suppression of CD4 + T-cell The horizontal line is plotted at the median. Whiskers show minimum to maximum. '+' indicates mean. Kruskal-Wallis test followed by Dunn's multiple comparison test was performed for data that were not normally distributed (*P ≤ 0Á05, **P ≤ 0Á01). [H]thymidine assay was set up with titrated doses of MBP Ac1-9 (4K) and irradiated APC. Again, the proliferation of CD4 + T cells isolated from mice that had received a transfer of PMN-MDSC was significantly reduced over a range of MBP Ac1-9 (4K) peptide concentrations compared with cells from mice that did not receive the transfer (Fig. 9b) . In addition, intracellular cytokine staining demonstrated a small but not significant reduction in the production of the pro-inflammatory cytokines interferon-c or IL-17 by CD4 + T cells from animals that had received a PMN-MDSC transfer, upon re-stimulation with PMA/ionomycin (Fig. 9c) .
PMN-MDSC ameliorate encephalogenicity of Th1 cells
Given the reduction in CD4 + T-cell proliferative capacity after adoptive transfer of PMN-MDSC ex vivo, we asked if PMN-MDSC would interfere with CD4 + T-cell pathogenicity. Therefore, MBP-specific CD4 + T cells were polarized in vitro under normal Th1 conditions either with or without the addition of PMN-MDSC, before adoptive transfer to Tg4 recipients to induce a passive form of EAE. The addition of PMN-MDSC during Th1 polarization led to a clear amelioration of EAE severity and to an enhanced recovery from disease, demonstrating their disease-limiting propensity ( Fig. 10 and Table 1 ).
Discussion
In this study, we show for the first time that MDSC, and PMN-MDSC in particular, accumulate during the course of EDI in various organs from the CNS to the periphery. The preferential expansion of PMN-MDSC over M-MDSC does not come as a complete surprise because PMN-MDSC represent the major pool of circulating and expanding MDSC in both mice and humans in the tumour environment, 26 revealing a 3 : 1 ratio of PMN-MDSC to M-MDSC. 27 The more pronounced accumulation of PMN-MDSC after the third dose of peptide treatment may result from the fact that Tg4 mice showed a peak in the amount of IL-6 and IL-17 after this dose. 5 These cytokines are known to mediate the accumulation of MDSC and their immunosuppressive function. [28] [29] [30] [31] The PMN-MDSC that we induced during antigen-specific peptide immunotherapy were able to reduce the proliferation of CD4 + T cells and expand CD4 + Foxp3 + T cells in vitro. Moreover, adoptive transfer of PMN-MDSC before priming of Tg4 mice with MBP Ac1-9 (4K) in complete Freund's adjuvant reduced the CD4 + T-cell proliferative response upon re-stimulation ex vivo. We found that PMN-MDSC were able to suppress naive CD4 + Tcell proliferation induced by either an antigen-specific or non-specific stimulus. Surprisingly, PMN-MDSC reduced the proliferative response of antigen-experienced T cells only when stimulated non-specifically with anti-CD3 + anti-CD28. A previous study showed that MDSC from the tumour site and spleen of the same mouse can differ in their ability to suppress CD8 + T-cell proliferation even though no phenotypic differences could be detected. 31 Both MDSC populations were able to suppress CD8 + T-cell proliferation in an antigen-specific manner; however, splenic MDSC did not suppress CD8 + T-cell proliferation in response to anti-CD3 + anti-CD28. These differences in suppression could be explained by the tumour environment, where suppressive factors are present that are absent in the spleen. But, all PMN-MDSC we studied were isolated from the spleen and only the method of CD4 + T-cell stimulation differed. So far, we have no definitive explanation as to why in our experiments antigen-experienced cells could be suppressed when stimulated with antibody but not when stimulated with antigen, but it could have to do with either the affinity of the interaction or the involvement of co-stimulatory or co-inhibitory molecules. It further remains to be determined if the fact that the antigen-experienced T cells in our experiments have had more than one previous antigen encounter affects their ability to be suppressed by MDSC.
Most of the published studies, as well as our own results, indicate that MDSC need direct cell-cell contact to exert their immunosuppressive function, which suggests that they act either through cell surface receptor-ligand interactions or through release of soluble mediators that act only in close proximity. 32 MDSC have previously been shown to use multiple mechanisms to suppress T- After checking for normality using the Shapiro-Wilk test the unpaired t-test was performed for normally distributed data (*P ≤ 0Á05, **P ≤ 0Á01, ***P ≤ 0Á001, ****P ≤ 0Á0001). Each dot represents one individual, n = 7 to n = 11. Pooled data from three independent experiments. (b) Single, viable PMN-MDSC were analysed for the expression of CD40, CD80, Galectin-9 and PD-L1. Horizontal lines indicate mean. After checking for normality using the Shapiro-Wilk test either unpaired t-test was performed for normally distributed data or the Mann-Whitney U-test for data that were not normally distributed (*P ≤ 0Á05, **P ≤ 0Á01). Each dot represents one individual, n = 7 to n = 11. Pooled data from three independent experiments. Unpaired t-test was applied to central nervous system data. Unpaired t-test was applied to Galectin-9 BLN data and PD-L1 data whereas the Mann-Whitney U-test was applied to spleen Galectin-9 data.
ª 2017 John Wiley & Sons Ltd, Immunology, 151, 26-42 cell proliferation. 14 The majority of studies have found an involvement of the enzymes arginase-1 and iNOS in MDSC-mediated suppression of T cells. 14, 15 However, the addition of an inhibitor of iNOS, L-NMMA did not ablate the suppressive activity of PMN-MDSC in our hands, whereas the arginase-1 inhibitor (BEC) restored CD4 + T-cell proliferation, which suggests a preferential role for arginase-1 in our model.
It has been suggested that the suppressive activity of MDSC is dependent on the immunomodulatory cytokine IL-10, 17 although this finding is not universally supported. 33 However, signalling through the IL-10R was found to be required to establish the suppressive phenotype in MDSC, 33 which supports our findings that although addition of a blocking anti-IL-10R antibody did not restore CD4 + T-cell proliferation, tolerization of IL-10-deficient animals showed a change in the phenotype of PMN-MDSC compared with IL-10-sufficient mice.
In addition to these soluble factors, the cell surface molecules PD-L1 and Galectin-9 have been suggested to mediate the T-cell-suppressive effect. 6, 18 In our study the blockade of either cell surface receptor separately during in vitro co-culture using neutralizing antibodies did not restore T-cell proliferation whereas the co-blockade of both molecules together led to the abrogation of suppression, indicating a synergistic effect.
The frequency of PMN-MDSC in mice with induced EAE was significantly higher in many of the organs examined than in mice that had been protected by EDI. This raises the question why animals are not protected from disease even though these potentially immunosuppressive PMN-MDSC arise. Our findings hint at the possibility that phenotypic differences between those PMN-MDSC that develop after EAE development and those that arise after tolerization contribute to their functional dichotomy. Compared with the PMN-MDSC of mice with EAE, we detected a higher expression of Galectin-9 and PD-L1 on PMN-MDSC in the spleen and lymph nodes with an increase of CD40 and a decrease of CD80 in the CNS compartment of tolerized animals. The exact role of CD40 in MDSC-mediated suppression remains unclear but Pan et al. 19 showed that CD40 expressed on MDSC is essential for their suppressive function and regulatory T-cell induction. This is supported by our in vitro findings, where blockade of CD40 abrogated PMN-MDSC suppression and restored CD4 + T-cell proliferation.
In recent years, the expression of CD80 on MDSC has been associated with immune suppression, 20 which corroborates our findings that the addition of anti-CD80 to our in vitro co-cultures led to abrogation of MDSC-mediated inhibition of CD4 + T-cell proliferation. This, however, is in direct contrast to our hypothesis that peptide treatment promotes a more suppressive PMN-MDSC phenotype in the CNS, as we found a reduced expression of CD80 on PMN-MDSC in the CNS of tolerized animals. The effect of CD80 expression on the function of PMN-MDSC remains unclear however, as it was shown previously that, in a rat model of kidney allograft tolerance, blood-derived CD80-positive MDSC have the same suppressive capacity as their CD80-negative counterparts. 34 Overall, it is unclear how important the phenotype of PMN-MDSC in the CNS is for the prevention of EAE as the maintenance of tolerance and prevention of disease development may very well be controlled in the periphery rather than the CNS. After all, removal of the spleen prevented successful tolerance induction and hence protection from disease. This was also shown previously in a model of experimental autoimmune uveoretinitis where splenectomy likewise abrogated the induction of tolerance. 35 PD-L1 expression on PMN-MDSC was increased only in the spleen and no other organs of tolerized animals. PD-L1 + PMN-MDSC could potentially interact with PD-1-expressing CD4 + T cells in the spleen. 5 Tumour-infiltrating MDSC from tumour-bearing mice have previously been shown to express high levels of PD-L1 and to be able to suppress the proliferation of CD8 + T cells.
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MDSC-mediated T-cell suppression may therefore be mediated by the PD-L1-PD-1 axis and this interaction is likely take to place in the spleen. Another important negative regulator of T-cell activity, TIM-3, was significantly up-regulated on CD4 + T cells in the spleen of tolerized animals that were protected from EAE in our study. 5 An earlier study described a potential role for the Tim-3/ Galectin-9 pathway in MDSC proliferation. 6 Our results suggest that MDSC-mediated plasticity of conventional T cells in the spleen, and not just the differentiation of regulatory T cells might, at least in part, be responsible for the protective effect of EDI. After all, our splenectomy experiments showed that animals without a spleen receiving EDI were still more susceptible to EAE than mice that retained their spleen. Our findings are Figure 7 . Splenectomy impairs the increase in the number of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) post escalating dose immunotherapy (EDI) and prevents tolerance induction. Tg4 mice underwent either a sham operation or splenectomy 14 days before EDI to induce tolerance or PBS only as a control. Thereafter, inguinal lymph nodes (ILN), brachial lymph nodes (BLNs), lungs and liver were removed and analysed by flow cytometry (each dot represents an animal), gated on single, viable cells. Horizontal lines in (a) and (b) indicate mean. After checking for normality using the Shapiro-Wilk test either analysis of variance (ANOVA) followed by Sidak's multiple comparison test was performed for normally distributed data or the Kruskal-Wallis test followed by Dunn's multiple comparison test for data that were not normally distributed (*P ≤ 0Á05, **P ≤ 0Á01, ****P ≤ 0Á0001). (a) Percentage of CD11b + Ly6G + PMN-MDSC in the ILN, BLN, lung and liver in splenectomized or sham-operated mice that have either been tolerized with MBP Ac1-9 (4Y) or received control treatment with PBS only. ANOVA followed by Sidak's multiple comparison test was applied to ILN (n = 6-7, pooled data from two independent experiments) and BLN data (n = 6-7, pooled data from two independent experiments). Kruskal-Wallis test followed by Dunn's multiple comparison test was applied to lung and liver data (n = 3-4, one experiment). (b) Absolute numbers of CD11b + Ly6G + PMN-MDSC in the ILN, BLN, lung and liver in splenectomized or sham-operated mice that have either been tolerized with MBP Ac1-9 (4Y) or received control treatment with PBS only. ANOVA followed by Sidak's multiple comparison test was applied to ILN (n = 6 or n = 7, pooled data from two independent experiments) and BLN data (n = 6 or n = 7, pooled data from two independent experiments). Kruskal-Wallis test followed by Dunn's multiple comparison test was applied to lung and liver data (n = 3 or n = 4, one experiment). (c) Tg4 mice underwent either sham operation or splenectomy 14 days before EDI to induce tolerance or were treated with PBS as a control. Subsequently, experimental autoimmune encephalomyelitis (EAE) was induced and animals were monitored daily for 20 days for signs of disease. Line graph shows disease scores over time (mean + SEM). Bar graph shows area under the curve (AUC, mean + SEM). One-way ANOVA with Tukey's multiple comparison post hoc test P ≤ 0.0001, n = 9 or n = 12 for each group, pooled data from three independent experiments, mean + SEM). [H]thymidine assay was set up. (a) Proliferative response of whole cell isolates from the spleen and ILN, after re-stimulation in vitro with titrated doses of MBP Ac1-9 (4K) (n = 6 to n = 8, pooled data from two independent experiments). Line graph shows mean AE SEM. After checking for normality using the Shapiro-Wilk test the unpaired t-test was performed for normally distributed data (**P ≤ 0Á01, ***P ≤ 0Á001, ****P ≤ 0Á0001). supported by a study where splenectomy before tolerance induction to ovalbumin did not affect the number of CD4 + regulatory T cells yet the establishment of skin tolerance could not be achieved. 36 Previous work implied that T cells need to migrate through the spleen to become encephalitogenic and cause disease, in a process known as T-cell licensing. 37 One could speculate that PMN-MDSC in the spleen may prevent T-cell licensing, although this will require further investigation.
Our work further provides evidence for a direct effect of PMN-MDSC on the encephalogenicity of Th1 cells, as T cells cultured in the presence of PMN-MDSC are less potent inducers of EAE. Animals developed less severe EAE symptoms and recovered faster from disease compared with animals that received Th1 cells polarized under normal conditions.
Overall, we demonstrate here that PMN-MDSC play an important role in tolerance induction during antigen-specific immunotherapy of autoimmune disease. Their differentiation should therefore be a prime target of treatment and may be an indicator of successful therapy. 
